| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
11,797 |
11,544 |
$1.12M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,421 |
3,421 |
$481K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
4,261 |
4,234 |
$165K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,850 |
1,826 |
$138K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,177 |
1,174 |
$98K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,138 |
3,038 |
$86K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
802 |
802 |
$77K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,559 |
4,529 |
$65K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
653 |
649 |
$21K |
| 87807 |
|
258 |
255 |
$3K |
| 96136 |
|
80 |
80 |
$3K |
| 80305 |
|
170 |
157 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
121 |
118 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
35 |
35 |
$2K |
| 99051 |
|
150 |
150 |
$936.00 |
| 81025 |
|
118 |
117 |
$873.24 |
| 90674 |
|
24 |
24 |
$306.65 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
12 |
12 |
$208.56 |
| 96127 |
|
12 |
12 |
$92.64 |